Paul Peter Tak

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. pmc NF-kappaB: a key role in inflammatory diseases
    P P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, The Netherlands
    J Clin Invest 107:7-11. 2001
  2. ncbi IFN-beta in rheumatoid arthritis
    Paul Peter Tak
    Division of Clinical Immunology and Rheumatology Academic Medical Center University of Amsterdam, The Netherlands
    Front Biosci 9:3242-7. 2004
  3. ncbi Chemokine inhibition in inflammatory arthritis
    Paul P Tak
    Division of Clinical Immunology and Rheumatology F4 218, Academic Medical Centre University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Best Pract Res Clin Rheumatol 20:929-39. 2006
  4. pmc The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium
    C A Wijbrandts
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 67:1139-44. 2008
  5. pmc Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
    C A Wijbrandts
    Department of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 68:1316-21. 2009
  6. pmc Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
    C A Wijbrandts
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 68:373-6. 2009
  7. pmc A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue
    A W R van Kuijk
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 68:1303-9. 2009
  8. pmc TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
    A W R van Kuijk
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, NL 1105 AZ Amsterdam, The Netherlands
    Ann Rheum Dis 69:301-4. 2010
  9. pmc Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
    M M J Herenius
    D ivision of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 70:1160-2. 2011
  10. pmc Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats
    J Adriaansen
    Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    J Gen Virol 88:1717-21. 2007

Detail Information

Publications123 found, 100 shown here

  1. pmc NF-kappaB: a key role in inflammatory diseases
    P P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, The Netherlands
    J Clin Invest 107:7-11. 2001
  2. ncbi IFN-beta in rheumatoid arthritis
    Paul Peter Tak
    Division of Clinical Immunology and Rheumatology Academic Medical Center University of Amsterdam, The Netherlands
    Front Biosci 9:3242-7. 2004
    ..Novel approaches leading to constitutive IFN-beta production at the site of inflammation may be required to induce clinical efficacy in patients...
  3. ncbi Chemokine inhibition in inflammatory arthritis
    Paul P Tak
    Division of Clinical Immunology and Rheumatology F4 218, Academic Medical Centre University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Best Pract Res Clin Rheumatol 20:929-39. 2006
    ..Innovative trial design may help to screen for potentially interesting chemokine antagonists in an early stage of development...
  4. pmc The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium
    C A Wijbrandts
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 67:1139-44. 2008
    ..To determine whether the heterogeneous clinical response to tumour necrosis factor (TNF)alpha blocking therapy in rheumatoid arthritis (RA) can be predicted by TNFalpha expression in the synovium before initiation of treatment...
  5. pmc Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
    C A Wijbrandts
    Department of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 68:1316-21. 2009
    ..Because atherogenesis is accelerated in RA this study was conducted to investigate whether anti-tumour necrosis factor (TNF) therapy could lead to sustained downregulation of systemic MIF levels and improvement in lipid profiles...
  6. pmc Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
    C A Wijbrandts
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 68:373-6. 2009
    ..To explore the effects of anti-tumour necrosis factor (TNF)alpha antibody therapy on bone mineral density (BMD) of the lumbar spine and femur neck in patients with rheumatoid arthritis (RA)...
  7. pmc A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue
    A W R van Kuijk
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 68:1303-9. 2009
    ..To determine which of the changes in synovial tissue correlates best with clinical response associated with effective therapy (adalimumab) to facilitate the planning of future studies with therapeutic agents for psoriatic arthritis (PsA)...
  8. pmc TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
    A W R van Kuijk
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, NL 1105 AZ Amsterdam, The Netherlands
    Ann Rheum Dis 69:301-4. 2010
    ....
  9. pmc Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
    M M J Herenius
    D ivision of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 70:1160-2. 2011
    ..The aim of this study was to test if adalimumab treatment could affect the influx of monocytes into the synovium...
  10. pmc Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats
    J Adriaansen
    Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    J Gen Virol 88:1717-21. 2007
    ..Additionally, a significant beneficial effect was observed on proteoglycan depletion and erosions. Thus, intra-articular overexpression of IFN-beta using a rAAV5 vector exhibits potential as an innovative therapy for the treatment of RA...
  11. pmc Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease
    Rogier M Thurlings
    Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Noord Holland, The Netherlands
    PLoS ONE 4:e7865. 2009
    ..Translation of these data into the human condition has been hampered by the lack of available techniques to analyze monocyte migration in man...
  12. pmc The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis
    Johan Lindberg
    Department of Gene Technology, School of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden
    PLoS ONE 5:e11310. 2010
    ..In this work we have investigated the transcriptional profile of synovial tissue sampled from RA patients before anti-TNF treatment with the aim to identify biomarkers predictive of response...
  13. pmc Synovial tissue response to treatment in rheumatoid arthritis
    Elsa Vieira-Sousa
    Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Portugal
    Open Rheumatol J 5:115-22. 2011
    ..In this paper we review the effects of RA treatments on the synovial tissue, including targeted therapies, with particular attention to their effect on synovial biomarkers...
  14. pmc The features of the synovium in early rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria
    Marleen G H van de Sande
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    PLoS ONE 7:e36668. 2012
    ..We describe the features of synovial inflammation in RA patients classified according to these new criteria...
  15. ncbi Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients
    Maria Boumans
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Rheumatology (Oxford) 52:1462-6. 2013
    ..The most cost-effective dosing regimen for rituximab treatment in RA is currently unknown. The objective of this study is to determine whether low rituximab serum levels are associated with progression of structural damage in RA patients...
  16. doi Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial
    Paul P Tak
    Clinical Immunology and Rheumatology, F4 105, AMC University of Amsterdam, Amsterdam 1100 DD, The Netherlands
    Ann Rheum Dis 72:337-44. 2013
    ..This clinical trial evaluated the safety and efficacy of CCX354-C in patients with rheumatoid arthritis (RA)...
  17. ncbi [Tailored therapy for rheumatic disease within reach]
    Lisa G M van Baarsen
    Academisch Medisch Centrum, afd Klinische Immunologie en Reumatologie, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 155:A3569. 2011
    ..The identification of biomarkers predictive of the clinical response to specific treatments in subsets of patients may soon become reality in a variety of diseases...
  18. pmc Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis
    R Klaasen
    Division of Clinical Immunology and Rheumatology, Room F4 105, Academic Medical Center University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Ann Rheum Dis 71:1510-6. 2012
    ....
  19. pmc A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm
    Paul P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, F4 105 Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Rheumatology (Oxford) 51:600-9. 2012
    ..This preliminary algorithm may contribute to more cost-effective treatment of RA, and provides the basis for more extensive algorithms when additional data become available...
  20. ncbi Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial
    P P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre and University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 64:360-70. 2012
    ..To evaluate the safety and efficacy of ocrelizumab plus methotrexate (MTX) or leflunomide (LEF) in patients with active rheumatoid arthritis (RA) and an inadequate response to tumor necrosis factor α inhibitors...
  21. pmc Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
    Paul P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 71:351-7. 2012
    ..In the IMAGEstudy, rituximab plus methotrexate (MTX) inhibited joint damage and improved clinical outcomes at 1 year in MTX-naïve patients with early active rheumatoid arthritis...
  22. pmc Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy
    Arno W R van Kuijk
    Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands
    Curr Rheumatol Rep 13:353-9. 2011
    ..Finally, a model for proof-of-principle study design using serial synovial biopsies is described, which could be used to predict clinical (in)efficacy in early clinical trial design in PsA...
  23. pmc Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study
    Eliza K Pontifex
    Department of Rheumatology, St Vincents University Hospital, Elm Park, Dublin 4, Ireland
    Arthritis Res Ther 13:R7. 2011
    ....
  24. pmc Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance
    Tineke Cantaert
    Academic Medical Center University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Arthritis Res Ther 12:219. 2010
    ..Finally, we discuss the clinical relevance of this proposed cross-regulation for biological therapies such as type I IFN or anti-TNFα treatment...
  25. pmc Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
    Geertje M Bartelds
    Department of Rheumatology, Jan van Breemen Institute, Dr, Jan van Breemenstraat 2, 1056AB Amsterdam, The Netherlands
    Arthritis Res Ther 12:R221. 2010
    ..Therefore, we investigated whether a mismatch in IgG allotypes between adalimumab and IgG in adalimumab-treated patients is associated with the development of AAA...
  26. pmc Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome
    Jelle L Vosters
    Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Arthritis Res Ther 11:R189. 2009
    ..The aim of this study was to assess the effect of a locally expressed tumor necrosis factor inhibitor on the salivary gland function and histopathology in an animal model of Sjögren's syndrome...
  27. pmc Rituximab treatment in rheumatoid arthritis: how does it work?
    Maria Jh Boumans
    Arthritis Res Ther 11:134. 2009
    ..This finding adds to the emerging evidence that lack of response to rituximab is associated with persistence of B lineage cells in specific body compartments...
  28. pmc A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis
    Joana Rf Abreu
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
    Arthritis Res Ther 12:R2. 2010
    ..Therefore, we assessed the ability of a cell-permeable Rac1 carboxy-terminal inhibitory peptide to modulate disease in mice with collagen-induced arthritis (CIA)...
  29. pmc Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis
    Judith van Holten
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, The Netherlands
    Arthritis Res Ther 6:R239-49. 2004
    ..The data support the view that IFN-beta is a potential therapy for RA that might help to diminish both joint inflammation and destruction by cytokine modulation...
  30. pmc Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis
    Jasper J Haringman
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, The Netherlands
    Arthritis Res Ther 7:R862-7. 2005
    ..The measurement of change in total positive cell numbers in synovial tissue can be determined reproducibly for various cell types by DIA in RA clinical trials...
  31. pmc Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis
    Sarah L Jongbloed
    Division of Immunology, Infection and Inflammation, 10 Alexandra Parade, Glasgow, G31 2ER, UK
    Arthritis Res Ther 8:R15. 2006
    ..Maturation is incomplete in the inflamed synovial compartment. Immature DCs in SF may contribute to the perpetuation of inflammation via sampling of the inflamed synovial environment, and in situ presentation of arthritogenic antigen...
  32. pmc Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis
    Christian Barthel
    Clinic for Immunology and Rheumatology, Hannover Medical School MHH, Carl Neuberg Strasse 1, Hannover 30625, Germany
    Arthritis Res Ther 11:R82. 2009
    ..We previously described the presence of nerve growth factor receptors in the inflamed synovial compartment. Here we investigated the presence of the corresponding nerve growth factors, with special focus on nerve growth factor (NGF)...
  33. pmc Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment
    Lisa Gm van Baarsen
    Department of Pathology, VU University Medical Center, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands
    Arthritis Res Ther 12:R11. 2010
    ..Therefore, we determined the effect of TNF blockade in rheumatoid arthritis (RA) on the type I IFN response gene activity in relation to clinical response...
  34. pmc The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue
    Joana R F Abreu
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
    Arthritis Res Ther 11:R121. 2009
    ..Here, we examine the potential relationship between RasGRF1 expression and MMP production in RA, reactive arthritis, and inflammatory osteoarthritis synovial tissue and FLS...
  35. pmc Mannose-binding lectin deficiency is associated with early onset of polyarticular juvenile rheumatoid arthritis: a cohort study
    Koert M Dolman
    Department of Pediatric Hematology, Emma Children s Hospital, Academic Medical Center, University of Amsterdam, Meibergdreef, Amsterdam, 1105 AZ, The Netherlands
    Arthritis Res Ther 10:R32. 2008
    ..The aim of our study was to determine whether genetically determined MBL deficiency is associated with susceptibility to juvenile rheumatoid arthritis (JRA) and whether MBL2 genotypes are associated with JRA severity...
  36. pmc Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
    Aleksander M Grabiec
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Arthritis Res Ther 10:226. 2008
    ....
  37. pmc Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation
    Sander W Tas
    Division of Clinical Immunology and Rheumatology F4 218, Academic Medical Center University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Arthritis Res Ther 8:R86. 2006
    ..These results indicate that IKK-beta-targeted NF-kappaB blockade using the NBD peptide could offer a new approach for the local treatment of arthritis...
  38. pmc Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study
    Amber Y Goedkoop
    Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Res Ther 6:R326-34. 2004
    ..In conclusion, low-dose infliximab treatment leads to decreased neoangiogenesis and deactivation of the endothelium, resulting in decreased cell infiltration and clinical improvement in psoriasis and psoriatic arthritis...
  39. pmc Distinct synovial immunopathology in Behçet disease and psoriatic arthritis
    Juan D Canete
    Arthritis Unit, Department of Rheumatology, Hospital Clinic de Barcelona and IDIBAPS, Villaroel 170, Barcelona 08036, Spain
    Arthritis Res Ther 11:R17. 2009
    ..The aim of the study was to investigate synovial immunopathology differences between early Behçet disease (BD) and psoriatic arthritis (PsA)...
  40. pmc CD97 neutralisation increases resistance to collagen-induced arthritis in mice
    Else N Kop
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, P, O, Box 22700, 1100 DE Amsterdam, The Netherlands
    Arthritis Res Ther 8:R155. 2006
    ..When treatment was started on day 35, CD97 mAb treatment had similar effects, albeit less pronounced. The results support the notion that CD97 contributes to synovial inflammation and joint destruction in arthritis...
  41. pmc Chemokine blockade: a new era in the treatment of rheumatoid arthritis?
    Jasper J Haringman
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Res Ther 6:93-7. 2004
    ..Review of these data suggests that this approach might lead to novel therapeutic strategies in rheumatoid arthritis and other chronic inflammatory disorders...
  42. pmc A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis
    Mario H Cardiel
    Centro de Investigacion Clinica de Morelia, Morelia, Virrey de Mendoza 1998 Int, 522 Col Félix Ireta, Mich 58070, Mexico
    Arthritis Res Ther 12:R192. 2010
    ....
  43. pmc Interferon-beta for treatment of rheumatoid arthritis?
    Judith van Holten
    Division of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, The Netherlands
    Arthritis Res 4:346-52. 2002
    ..This notion is supported by recent studies showing a critical role for IFN-beta in bone homeostasis...
  44. doi Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis
    Maria J H Boumans
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, The Netherlands
    Ann Rheum Dis 71:108-13. 2012
    ..To examine how rituximab may result in the inhibition of joint destruction in rheumatoid arthritis (RA) patients...
  45. ncbi Effects of infliximab treatment on rheumatoid synovial tissue
    Paul P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    J Rheumatol Suppl 74:31-4. 2005
    ..Future studies should focus on the evaluation of apoptosis within the first 48 hours after initiation of therapy in RA to exclude the possibility that the effects occur very early after infliximab infusion...
  46. doi Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study
    M J H Boumans
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, The Netherlands
    Ann Rheum Dis 71:180-5. 2012
    ..The authors assessed the safety, tolerability, pharmacokinetics, pharmacodynamics and initial efficacy of the humanised monoclonal antibody ASK8007, which blocks osteopontin...
  47. doi Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis
    Maria J H de Hair
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    J Rheumatol 38:2068-72. 2011
    ....
  48. pmc Advances in rheumatology: new targeted therapeutics
    Paul P Tak
    Department of Medicine, Division of Clinical Immunology and Rheumatology F4 105, Academic Medical Center University of Amsterdam, P O Box 22700, 1100 DE Amsterdam, The Netherlands
    Arthritis Res Ther 13:S5. 2011
    ..The key challenge is identifying how best to integrate these new, advanced therapies into daily practice...
  49. doi Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
    P P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 70:39-46. 2011
    ..The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX...
  50. ncbi Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment?
    Paul P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, 1100 DE Amsterdam, The Netherlands
    J Rheumatol Suppl 72:25-6. 2005
    ..This suggests that these are key effector cells in the pathogenesis. In addition, it provides a biomarker that can be used in clinical trials...
  51. ncbi Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases
    P P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands
    Immunol Today 21:78-82. 2000
    ..The development of mutations in the p53 tumor suppressor gene and other key regulatory genes could help convert inflammation into chronic disease in rheumatoid arthritis and other inflammatory disorders...
  52. pmc Apoptosis and p53 expression in rat adjuvant arthritis
    P P Tak
    Division of Rheumatology, UCSD School of Medicine, La Jolla, California, USA
    Arthritis Res 2:229-35. 2000
    ....
  53. ncbi [Blockade of chemokines in chronic inflammatory diseases]
    J J Haringman
    Academisch Medisch Centrum Universiteit van Amsterdam, afd Klinische Immunologie en Reumatologie, F4 218, Meibergdreef 9, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 148:1760-4. 2004
    ..The first results have been reported in patients with rheumatoid arthritis and these seem to confirm the potency of this treatment...
  54. ncbi Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study
    P P Tak
    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 58:61-72. 2008
    ..The purpose of this study was to investigate the tolerability, pharmacokinetics, and pharmacodynamics of atacicept treatment in patients with rheumatoid arthritis (RA) and to collect exploratory data on clinical outcomes...
  55. ncbi Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue
    Tom J M Smeets
    Division of Clinical Immunology and Rheumatology, F4 218 Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 48:2155-62. 2003
    ..To determine whether treatment with the chimeric anti-tumor necrosis factor alpha antibody infliximab could reduce cellularity by the induction of apoptosis in synovial tissue...
  56. pmc Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent
    J Adriaansen
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 66:1143-50. 2007
    ....
  57. doi Altered BANK1 expression is not associated with humoral autoimmunity in chronic joint inflammation
    Tineke Cantaert
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Rheumatology (Oxford) 52:252-60. 2013
    ....
  58. pmc Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
    R M Thurlings
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Ann Rheum Dis 67:917-25. 2008
    ..To investigate the synovial tissue in patients with rheumatoid arthritis (RA) treated with rituximab and to identify possible predictors of clinical response...
  59. pmc Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis
    J J Haringman
    Division of Clinical Immunology and Rheumatology, F4 218, Academic Medical Centre University of Amsterdam, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Ann Rheum Dis 64:834-8. 2005
    ..Previous work identified synovial sublining macrophage numbers as a potential biomarker for clinical efficacy in rheumatoid arthritis...
  60. ncbi Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab
    Marieke M J Herenius
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Occup Environ Med 52:618-21. 2010
    ..To assess the effect of 12-month treatment with adalimumab on work ability, quality of life, and fatigue in patients with active rheumatoid arthritis (RA)...
  61. doi SNAPIN: an endogenous Toll-like receptor ligand in rheumatoid arthritis
    Bo Shi
    Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611 2909, USA
    Ann Rheum Dis 71:1411-7. 2012
    ..The objective of this study was to identify endogenous TLR ligands expressed in RA synovial tissue (ST) based on their ability to bind the extracellular domains of TLR2 or TLR4...
  62. ncbi Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation
    C E Vergunst
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre University of Amsterdam, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Rheumatology (Oxford) 46:1773-8. 2007
    ..Studies in animal models of RA have suggested therapeutic potential of C5aR blockade. In this study, we examined the effects of the C5aR blockade on synovial inflammation in RA patients...
  63. pmc Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy
    J Adriaansen
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 64:1677-84. 2005
    ..Gene therapy of the joint has great potential as a new therapeutic approach for the treatment of rheumatoid arthritis (RA). The vector chosen is of crucial importance for clinical success...
  64. pmc Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis
    A Y Goedkoop
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre University of Amsterdam, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Ann Rheum Dis 63:769-73. 2004
    ..Tumour necrosis factor alpha (TNFalpha) blockade using infliximab, a chimeric anti-TNFalpha antibody, is an effective treatment for both psoriasis and psoriatic arthritis (PsA)...
  65. pmc Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis
    J J Haringman
    Division of Clinical Immunology and Rheumatology F4 218, Department of Internal Medicine, Academic Medical Centre University of Amsterdam, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Ann Rheum Dis 65:294-300. 2006
    ..Chemokine receptors and chemokines have a crucial role in leucocyte recruitment into inflamed tissue...
  66. pmc Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
    G J Wolbink
    Jan van Breemen Institute, Amsterdam, The Netherlands
    Ann Rheum Dis 64:704-7. 2005
    ..To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid arthritis (RA)...
  67. pmc Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis
    J J Haringman
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre University of Amsterdam, The Netherlands
    Ann Rheum Dis 62:715-21. 2003
    ..Chemokines affecting monocytes/macrophages are considered potential therapeutic targets, but no studies of the effects of blocking the chemokine repertoire in humans with a chronic inflammatory disease have been reported...
  68. pmc Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade
    T Cantaert
    Academic Medical Center University of Amsterdam, The Netherlands
    Ann Rheum Dis 68:1022-9. 2009
    ..This study assessed whether similar mechanisms contribute to break peripheral B-cell tolerance in humans by studying the induction of antinuclear antibodies by tumour necrosis factor blockade in spondyloarthritis...
  69. ncbi Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation
    P P Tak
    University of California (San Diego) School of Medicine, La Jolla, USA
    Arthritis Rheum 44:1897-907. 2001
    ..IKKbeta-dn-treated animals. CONCLUSION: IKKbeta plays a key role in rodent synovial inflammation. Intraarticular gene therapy to inhibit IKKbeta activity represents an attractive strategy for the treatment of chronic arthritis...
  70. doi Work ability: a new outcome measure in rheumatoid arthritis?
    H G Raterman
    Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
    Scand J Rheumatol 39:127-31. 2010
    ..To assess the relationship between disease activity and work ability, quality of life (QoL), and fatigue in patients with RA during a 12-month course of the tumour necrosis factor (TNF)-blocking agent adalimumab...
  71. pmc Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis
    J van Holten
    Division of Clinical Immunology and Rheumatology F4 218, Academic Medical Centre, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Ann Rheum Dis 64:1780-2. 2005
    ..IFNbeta may have immunomodulatory effects in rheumatoid arthritis (RA) and its increased production in RA synovium may be a reactive attempt to inhibit inflammation...
  72. doi Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis
    B Vandooren
    Academic Medical Center University of Amsterdam, The Netherlands
    Ann Rheum Dis 68:1044-50. 2009
    ..In mice, melanoma inhibitory activity (MIA) is a chondrocyte-specific molecule with similar regulation to collagen type II. As MIA is a small secreted protein, its value as cartilage biomarker in human inflammatory arthritis was assessed...
  73. pmc Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis
    M C Kraan
    Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Amsterdam Academic Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 63:1056-61. 2004
    ..T cells have a pivotal role in RA. Leflunomide inhibits pyrimidine biosynthesis, to which T cells are especially susceptible, and therefore may have a different cytokine profile than methotrexate...
  74. ncbi The Academic Medical Center Linear Disability Score item bank: psychometric properties of a new generic disability measure in rheumatoid arthritis
    Nadine Weisscher
    Department of Neurology, Academic Medical Center, University of Amsterdam, The Netherlands
    J Rheumatol 34:1222-8. 2007
    ..To determine the psychometric properties of the Academic Medical Center (AMC) Linear Disability Scale (ALDS) item bank in a population of patients with rheumatoid arthritis (RA)...
  75. doi The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events
    Radjesh J Bisoendial
    Department of Clinical Immunology and Rheumatology, University of Amsterdam, The Netherlands
    Semin Thromb Hemost 36:452-7. 2010
    ....
  76. pmc The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8)
    M C Kraan
    Division of Clinical Immunology and Rheumatology, Department of Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Arthritis Res 3:65-71. 2001
    ..In particular, CXCL8 protein levels were specifically increased in CI joints compared with CU joints, which was confirmed by immunohistochemistry and in situ hybridization...
  77. pmc A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
    J van Holten
    Academic Medical Centre, University of Amsterdam, Netherlands
    Ann Rheum Dis 64:64-9. 2005
    ..To assess the efficacy of interferon beta (IFN beta) in combination with methotrexate in treatment of patients with rheumatoid arthritis...
  78. ncbi Critical determinants of cardiovascular risk in rheumatoid arthritis
    R J Bisoendial
    Department of Clinical Immunology and Rheumatology, Room F4 218, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands
    Curr Pharm Des 17:21-6. 2011
    ..Consequently, aggressive control of disease activity has been suggested to be instrumental for cardiovascular risk reduction. In the present review, we focus on these critical determinant that promote premature atherosclerosis in RA...
  79. pmc T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis
    M C Kraan
    Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Amsterdam Academic Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 63:483-8. 2004
    ..To determine immunohistological markers in synovial tissue of patients with early rheumatoid arthritis (RA) which are associated with unfavourable disease outcome...
  80. pmc Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis
    M C Kraan
    Division of Clinical Immunology and Rheumatology, Department of Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 60:296-8. 2001
    ..This study aimed at determining the sensitivity of DIA compared with semiquantitative analysis (SQA)...
  81. ncbi CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells
    P H J Remans
    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 54:3135-43. 2006
    ..This study was undertaken to investigate the mechanisms leading to production of reactive oxygen species (ROS) and oxidative stress in RA synovial T lymphocytes...
  82. pmc Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome
    M R Kok
    Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
    Ann Rheum Dis 62:1038-46. 2003
    ....
  83. pmc Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA
    T J Smeets
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 60:561-5. 2001
    ..This study aimed at defining the cell infiltrate and mediators of joint destruction in ST selected at arthroscopy from the CPJ in patients with RA who did not require joint surgery...
  84. pmc Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis
    T J M Smeets
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 62:635-8. 2003
    ..Synovial tissue (ST) from end stage destructive rheumatoid arthritis (RA) and arthroscopic biopsies obtained during active inflammation might exhibit different characteristics...
  85. ncbi Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes
    J Adriaansen
    Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Rheumatology (Oxford) 45:656-68. 2006
    ..This review gives an overview of some promising vectors used in RA research. Furthermore, several therapeutic genes are discussed that could be used for gene therapy in RA patients...
  86. ncbi [Prolonged effect of intra-articularly administered corticosteroids in combination with arthroscopic lavage in patients with an inflammatory arthritis of the knee]
    D M Gerlag
    Academisch Medisch Centrum Universiteit van Amsterdam, afd Klinische Immunologie en Reumatologie, Amsterdam
    Ned Tijdschr Geneeskd 152:1953-5. 2008
    ....
  87. ncbi The role of chemokines in rheumatoid arthritis and osteoarthritis
    C E Vergunst
    Division of Clinical Immunology and Rheumatology, Academic Medical Centre University of Amsterdam, The Netherlands
    Scand J Rheumatol 34:415-25. 2005
    ..Chondrocytes, for instance, express several chemokine receptors. Elucidating their function may provide new insights into joint degradation in RA as well as in other conditions, including osteoarthritis (OA)...
  88. ncbi Phosphoinositide 3-kinase signalling and FoxO transcription factors in rheumatoid arthritis
    K A Reedquist
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Room K0 140, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Biochem Soc Trans 34:727-30. 2006
    ..This review highlights recent advances in our understanding of PI3K signalling pathways, in particular regulation of FoxO (forkhead box O) transcription factors, and their relevance to RA...
  89. doi Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation
    J L Hoving
    Coronel Institute of Occupational Health and Research Centre for Insurance Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands
    Scand J Rheumatol 38:246-50. 2009
    ..The objective of this exploratory study was to evaluate the effects and costs of a 6-month course of tumour necrosis factor (TNF) inhibitors on work ability, quality of life, and fatigue in patients with rheumatoid arthritis (RA)...
  90. ncbi [Arthritis psoriatica]
    M A De Rie
    Academisch Medisch Centrum Universiteit van Amsterdam, Afd Huidziekten, Amsterdam
    Ned Tijdschr Geneeskd 151:1716-22. 2007
    ..The Dutch Society of Dermatology and Venereology and the Dutch Society of Rheumatology have drawn up guidelines for the treatment of patients with psoriasis and psoriatic arthritis using these so-called biologics...
  91. ncbi Systemic inflammation as a risk factor for atherothrombosis
    S I van Leuven
    Academic Medical Center, Department of Vascular Medicine, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Rheumatology (Oxford) 47:3-7. 2008
    ....
  92. ncbi Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
    R M Thurlings
    Academic Medical Centre University of Amsterdam, The Netherlands
    Ann Rheum Dis 69:409-12. 2010
    ....
  93. ncbi Intracellular free radical production in synovial T lymphocytes from patients with rheumatoid arthritis
    P H J Remans
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 52:2003-9. 2005
    ..To investigate the cellular and molecular sources of oxidative stress in patients with rheumatoid arthritis (RA) through analysis of the production of reactive oxygen species (ROS) in synovium...
  94. pmc Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment
    A W R van Kuijk
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, F4 218, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Ann Rheum Dis 65:1551-7. 2006
    ..The synovial tissue is a primary target of many inflammatory arthropathies, including psoriatic arthritis (PsA). Identification of proinflammatory molecules in the synovium may help to identify potentially therapeutic targets...
  95. ncbi Where the immune response meets the vessel wall
    R J Bisoendial
    Department of Clinical Immunology and Rheumatology, University of Amsterdam, The Netherlands
    Neth J Med 67:328-33. 2009
    ..In this review, we focus on pathophysiology and observational evidence of cardiovascular risk in different prototypes of IMIDs...
  96. ncbi [Pseudogout in 3 patients with presumed therapy-resistant rheumatoid arthritis]
    C E Vergunst
    Academisch Medisch Centrum Universiteit van Amsterdam, afd Klinische Immunologie en Rheumatologie, Meibergdreef 9, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 149:773-7. 2005
    ..It is important to distinguish pseudogout from RA because their treatment is completely different. Furthermore, pseudogout can be the first or sole symptom of a metabolic disorder...
  97. ncbi Inhibition of forkhead box class O family member transcription factors in rheumatoid synovial tissue
    J Ludikhuize
    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 56:2180-91. 2007
    ..The present study was undertaken to examine whether FoxO transcription factors are differentially inactivated in RA synovial tissue, and whether this inactivation correlates with laboratory and clinical parameters of disease activity...